The high-dose Ceperognastat treatment appeared to significantly worsen symptoms and elevate off-target adverse events; however, there was a reduction in hippocampal atrophy, less temporal lobe tau pathology (as measured by PET imaging with flortaucipir), and lower plasma pTau-217 levels. This evidence concerns the gene MAPT and hippocampal atrophy.